Пробиотики: нерешенные вопросы

В.А.  Андреев; Ольга Ульяновна Стецюк; Ирина Вениаминовна Андреева

doi:10.36488/cmac.2022.4.345-360

Пробиотики: нерешенные вопросы

Клиническая микробиология и антимикробная химиотерапия. 2022; 24(4):345-360

Андреев В.А., Стецюк О.У., Андреева И.В.

10.36488/cmac.2022.4.345-360

пробиотики пробиотические микроорганизмы фармабиотики антибиотики антибиотикорезистентность дозирование противопоказания

Раздел

Антимикробные препараты

Тип

Обзор

Публикация

Клиническая микробиология и антимикробная химиотерапия. 2022; 24(4):345-360

Аннотация Авторы Литература PDF Статистика Репринты

Аннотация

Исследования последних десятилетий убедительно подтвердили пользу для здоровья пробиотических микроорганизмов. Однако в настоящее время есть целый ряд вопросов о пробиотиках, которые пока либо остаются без ответов, либо ответы на них не всегда однозначны. В данной статье с позиций доказательной медицины освещены нерешенные или неясные на текущий момент вопросы, в частности, касающиеся регуляторного статуса пробиотиков, возможности их назначения совместно с антибиотиками, влияния использования пробиотиков на риск развития и распространения антибиотикорезистентности, подходов к дозированию и длительности применения пробиотиков, противопоказаний, и некоторые другие спорные аспекты их применения.

Андреев В.А.

ФГБОУ ВО «Смоленский государственный медицинский университет» Минздрава России, Смоленск, Россия

Стецюк Ольга Ульяновна

0000-0002-7316-9187

НИИ антимикробной химиотерапии ФГБОУ ВО СГМУ Минздрава России, Смоленск, Россия

Андреева Ирина Вениаминовна

Irina.Andreeva@antibiotic.ru

0000-0001-7916-1488

НИИ антимикробной химиотерапии ФГБОУ ВО СГМУ Минздрава России, Смоленск, Россия

1. Lee Y.K., Salminen S. The coming of age of probiotics. Trends Food Sci Technol. 1995;6:241-245. DOI: 10.1016/S0924-2244(00)89085-8
2. Probiotics Market by Product Type (Functional Food & Beverages, Dietary Supplements, and Feed), Ingredient (Bacteria and Yeast), End User (Human and Animal), Distribution Channel, and Region – Global Forecast to 2027. Available at: www.marketsandmarkets.com/Market-Reports/probiotic-market-advanced-technologiesand-global-market-69.html. Accessed November, 2022.
3. Ivashkin V.T., Mayev I.V., Abdulganieva D.I., Alekseenko S.A., Gorelov A.V., Zakharova I.N., et al. Practical recommendations of scientific society for the study of human microbiome and the Russian Gastroenterological Association on use of probiotics, prebiotics, synbiotics and functional foods in treatment and prevention of gastroenterological diseases in children and adults. Russian journal of gastroenterology, hepatology, coloproctology. 2021;31(2):65-91. Russian. (Ивашкин В.Т., Маев И.В., Абдулганиева Д.И., Алексеенко С.А., Горелов А.В., Захарова И.Н. и соавт. Практические рекомендации Научного сообщества по содействию клиническому изучению микробиома человека (НСОИМ) и Российской гастроэнтерологической ассоциации (РГА) по применению пробиотиков, пребиотиков, синбиотиков и обогащенных ими функциональных пищевых продуктов для лечения и профилактики заболеваний гастроэнтерологического профиля у детей и взрослых. Российский журнал гастроэнтерологии, гепатологии, колопроктологии. 2021;31(2):65-91.) DOI: 10.22416/13824376-2021-31-2-65-91
4. GOST R 52349-2005 Food products. Functional food products. Terms and definitions (with Amendment No. 1). Date of effect 2006-07- 01. Russian. (ГОСТ Р 523492005. Продукты пищевые. Продукты пищевые функциональные. Термины и определения (с Изменением № 1).)
5. GOST P 55577-2013. National Standard of the Russian Federation. Specialized and functional food products. Information on distinguishing characters and efficacy. Russian. (ГОСТ Р 55577-2013. Национальный стандарт Российской Федерации. Продукты пищевые специализированные и функциональные. Информация об отличительных признаках и эффективности.)
6. GOST R 54059-2010. National Standard of the Russian Federation. Functional food products. Functional food ingredients. Classification and general requirements. Russian. (ГОСТ Р 54059-2010. Национальный стандарт Российской Федерации. Продукты пищевые функциональные. Ингредиенты пищевые функциональные. Классификация и общие требования.)
7. TR CU 021/2011 Technical Regulation of the Customs Union “On Food Safety” of 9 December, 2011, No. 880 (as amended on 8 August, 2019). Russian. (ТР ТС 021/2011. Технический регламент Таможенного союза «О безопасности пищевой продукции» от 9 декабря 2011 года № 880 (с изменениями на 8 августа 2019 года).)
8. SanPiN 2.3.2.1290 – 03.2.3.2. (p 2.1) «Food raw materials and food products. Hygienic requirements for the organization of dietary supplements production and turnover. Sanitary and epidemiological rules and regulations”, approved by the Chief Public Health Officer of the Russian Federation on 17.04.2003 № 50. Russian. (СанПиН 2.3.2.1290 – 03.2.3.2. (п 2.1) «Продовольственное сырье и пищевые продукты. Гигиенические требования к организации производства и оборота биологически активных добавок к пище (БАД). Санитарноэпидемиологические правила и нормативы», утв. Главным государственным санитарным врачом РФ 17.04.2003 N 50.)
9. Federal Law of the Russian Federation of 12 April, 2010, No. 61-FZ «On Regulation of Drugs». Russian. (Федеральный закон «Об обращении лекарственных средств» от 12.04.2010 N 61-ФЗ.)
10. Order of the Ministry of Health of the Russian Federation No. 403n of 11 July, 2017, “On approval of rules for dispensing drugs for medical use, including immunobiological drugs, by pharmaceutical organisations and individual entrepreneurs licensed to conduct pharmaceutical activities” of 12 September, 2017. Russian. (Приказ Министерства здравоохранения РФ от 11 июля 2017 г. № 403н «Об утверждении правил отпуска лекарственных препаратов для медицинского применения, в том числе иммунобиологических лекарственных препаратов, аптечными организациями, индивидуальными предпринимателями, имеющими лицензию на фармацевтическую деятельность» от 12 сентября 2017 г.)
11. General pharmacopoeial article “Probiotics” OFS.1.7.1. 0008.15 of the Ministry of Health of the Russian Federation. Russian. (Общая фармакопейная статья «Пробиотики» ОФС.1.7. 1.0008.15 Министерства здравоохранения РФ.)
12. Lee E.S., Song E.J., Nam Y.D., Lee S.Y. Probiotics in human health and disease: from nutribiotics to pharmabiotics. J Microbiol. 2018;56(11):773-782. DOI: 10.1007/s12275-018-8293-y
13. Hill C., Guarner F., Reid G., Gibson G.R., Merenstein D.J., Pot B., et al. Expert consensus document. The International Scientific Association for Probiotics and Prebiotics consensus statement on the scope and appropriate use of the term probiotic. Nat Rev Gastroenterol Hepatol. 2014;11(8):506-514. DOI: 10.1038/nrgastro.2014.66
14. Shanahan F., Stanton C., Ross P., Hill C. Pharmabiotics, bioactives from mining host-microbe-dietary interactions. Funct Food Rev. 2009;1:20-25.
15. LeBegue C.E., Love B.L., Wyatt M.D. Microbes as drugs: the potential of pharmabiotics. Pharmacotherapy. 2020;40(2):102-106. DOI: 10.1002/phar.2357
16. Hill C. Probiotics and pharmabiotics: alternative medicine or an evidence-based alternative? Bioeng Bugs. 2010;1(2):79-84. DOI: 10.4161/bbug.1.2.10796
17. D’Aimmo M.R., Modesto M., Biavati B. Antibiotic resistance of lactic acid bacteria and Bifidobacterium spp. isolated from dairy and pharmaceutical products. Int J Food Microbiol. 2007;115(1):35-42. DOI: 10.1016/j.ijfoodmicro.2006.10.003
18. Klare I., Konstabel C., Werner G., Huys G., Vankerckhoven V., Kahlmeter G., et al. Antimicrobial susceptibilities of Lactobacillus, Pediococcus and Lactococcus human isolates and cultures intended for probiotic or nutritional use. J Antimicrob Chemother. 2007;59(5):900-912. DOI: 10.1093/jac/dkm035
19. Anisimova E.A., Yarullina D.R. Antibiotic resistance of Lactobacillus strains. Curr Microbiol. 2019;76(12):14071416. DOI: 10.1007/s00284-019-01769-7
20. Comunian R., Daga E., Dupré I., Paba A., Devirgiliis C., Piccioni V., et al. Susceptibility to tetracycline and erythromycin of Lactobacillus paracasei strains isolated from traditional Italian fermented foods. Int J Food Microbiol. 2010;138(1-2):151-156. DOI: 10.1016/j.ijfoodmicro.2009.11.018
21. Masco L., Van Hoorde K., De Brandt E., Swings J., Huys G. Antimicrobial susceptibility of Bifidobacterium strains from humans, animals and probiotic products. J Antimicrob Chemother. 2006;58(1):85-94. DOI: 10.1093/jac /jac/dkl197
22. Moubareck C., Gavini F., Vaugien L., Butel M.J., DoucetPopulaire F. Antimicrobial susceptibility of bifidobacteria. J Antimicrob Chemother. 2005;55(1):38-44. DOI: 10.1093/jac/dkh495
23. Xu J., Liu X., Yang B., Li Z. [Antimicrobial susceptibility of probiotics]. Wei Sheng Yan Jiu. 2008;37(3):354-356. PMID: 18646539.
24. Neut C., Mahieux S., Dubreuil L.J. Antibiotic susceptibility of probiotic strains: is it reasonable to combine probiotics with antibiotics? Med Mal Infect. 2017;47(7):477-483. DOI: 10.1016/j.medmal.2017.07.001
25. McFarland L.V. From yaks to yogurt: the history, development, and current use of probiotics. Clin Infect Dis. 2015;60(Suppl. 2):S85-90. DOI: 10.1093/cid/civ054
26. Adams C.A. The probiotic paradox: live and dead cells are biological response modifiers. Nutr Res Rev. 2010;23(1):3746. DOI: 10.1017/S0954422410000090
27. Lebeer S., Vanderleyden J., De Keersmaecker S.C. Host interactions of probiotic bacterial surface molecules: comparison with commensals and pathogens. Nat Rev Microbiol. 2010;8(3):171-184. DOI: 10.1038/nrmicro2297
28. Corr S.C., Hill C., Gahan C.G. Understanding the mechanisms by which probiotics inhibit gastrointestinal pathogens. Adv Food Nutr Res. 2009;56:1-15. DOI: 10.1016/S1043-4526(08)00601-3
29. D’Souza A.L., Rajkumar C., Cooke J., Bulpitt C.J. Probiotics in prevention of antibiotic associated diarrhoea: metaanalysis. BMJ. 2002;324(7350):1361. DOI: 10.1136/bmj.324.7350.1361
30. Cremonini F., Di Caro S., Nista E.C., Bartolozzi F., Capelli G., Gasbarrini G., et al. Meta-analysis: the effect of probiotic administration on antibiotic-associated diarrhoea. Aliment Pharmacol Ther. 2002;16(8):1461-1467. DOI: 10.1046/j.1365-2036.2002.01318.x
31. Szajewska H., Ruszczyński M., Radzikowski A. Probiotics in the prevention of antibiotic-associated diarrhea in children: a meta-analysis of randomized controlled trials. J Pediatr. 2006;149(3):367-372. DOI: 10.1016/j.jpeds.2006.04.053
32. Johnston B.C., Goldenberg J.Z., Vandvik P.O., Sun X., Guyatt G.H. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2011;11:CD004827. DOI: 10.1002/14651858.CD004827.pub3
33. Hempel S., Newberry S.J., Maher A.R., Wang Z., Miles J.N., Shanman R., et al. Probiotics for the prevention and treatment of antibiotic-associated diarrhea: a systematic review and meta-analysis. JAMA. 2012;307(18):19591969. DOI: 10.1001/jama.2012.3507
34. Goldenberg J.Z., Ma S.S., Saxton J.D,. Martzen M.R., Vandvik P.O., Thorlund K., et al. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2013;5: CD006095. DOI: 10.1002/14651858.CD006095.pub3
35. Goldenberg J.Z., Lytvyn L., Steurich J., Parkin P., Mahant S., Johnston B.C. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2015;12:CD004827. DOI: 10.1002/14651858.CD004827.pub4
36. Szajewska H., Kołodziej M. Systematic review with metaanalysis: Lactobacillus rhamnosus GG in the prevention of antibiotic-associated diarrhoea in children and adults. Aliment Pharmacol Ther. 2015;42(10):1149-1157. DOI: 10.1111/apt.13404
37. Jafarnejad S., Shab-Bidar S., Speakman J.R., Parastui K., Daneshi-Maskooni M., Djafarian K. Probiotics reduce the risk of antibiotic-associated diarrhea in adults (1864 years) but not the elderly (> 65 years): a metaanalysis. Nutr Clin Pract. 2016;31(4):502-513. DOI: 10.1177/0884533616639399
38. Goldenberg J.Z., Yap C., Lytvyn L., Lo C.K., Beardsley J., Mertz D., Johnston B.C. Probiotics for the prevention of Clostridium difficile-associated diarrhea in adults and children. Cochrane Database Syst Rev. 2017;12: CD006095. DOI: 10.1002/14651858.CD006095.pub4
39. Shen N.T., Maw A., Tmanova L.L., Pino A., Ancy K., Crawford C.V., et al. Timely use of probiotics in hospitalized adults prevents Сlostridium difficile infection: a systematic review with meta-regression analysis. Gastroenterology. 2017;152(8):1889-1900. DOI: 10.1053/j.gastro.2017.02.003
40. Blaabjerg S., Artzi D.M., Aabenhus R. Probiotics for the prevention of antibiotic-associated diarrhea in outpatients – a systematic review and meta-analysis. Antibiotics (Basel). 2017;6(4):21. DOI: 10.3390/antibiotics6040021
41. Guo Q., Goldenberg J.Z., Humphrey C., El Dib R., Johnston B.C. Probiotics for the prevention of pediatric antibiotic-associated diarrhea. Cochrane Database Syst Rev. 2019;4:CD004827. DOI: 10.1002/14651858.CD004827.pub5
42. Ma Y., Yang J.Y., Peng X., Xiao K.Y., Xu Q., Wang C. Which probiotic has the best effect on preventing Clostridium difficile-associated diarrhea? A systematic review and network meta-analysis. J Dig Dis. 2020;21(2):69-80. DOI: 10.1111/1751-2980.12839
43. Goodman C., Keating G., Georgousopoulou E., Hespe C., Levett K. Probiotics for the prevention of antibiotic-associated diarrhoea: a systematic review and meta-analysis. BMJ Open. 2021;11(8):e043054. DOI: 10.1136/bmjopen-2020-043054
44. Liao W., Chen C., Wen T., Zhao Q. Probiotics for the prevention of antibiotic-associated diarrhea in adults: a meta-analysis of randomized placebo-controlled trials. J Clin Gastroenterol. 2021;55(6):469-480. DOI: 10.1097/MCG.0000000000001464
45. Williams Zhang L., Zeng X., Guo D., Zou Y, Gan H., Huang X. Early use of probiotics might prevent antibioticassociated diarrhea in elderly (> 65 years): a systematic review and meta-analysis. BMC Geriatr. 2022;22(1):562. DOI: 10.1186/s12877-022-03257-3
46. WGO Practice Guideline. Probiotics and prebiotics. World Gastroenterology Organization. 2012. Available at: www.worldgastroenterology.org/guidelines/global-guidelines/probiotics-and-prebiotics. Accessed November 16, 2022.
47. Szajewska H., Canani R.B., Guarino A., Hojsak I., Indrio F., Kolacek S., et al; ESPGHAN Working Group for Probiotics and Prebiotics. Probiotics for the prevention of antibiotic-associated diarrhea in children. J Pediatr Gastroenterol Nutr. 2016;62(3):495-506. DOI: 10.1097/MPG.0000000000001081
48. Guarner F., Sanders M.E., Eliakim R., Fedorak R., Gangl A., Garisch J., et al. World Gastroenterology Organization Global Guidelines. Probiotics and prebiotics. February 2017. Available at: www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebioticsenglish-2017.pdf. Accessed November 16, 2022.
49. Williams N.T. Probiotics. Am J Health Syst Pharm. 2010;67(6):449-458. DOI: 10.2146/ajhp090168
50. Malfertheiner P., Megraud F., O’Morain C.A., Gisbert J.P., Kuipers E.J., Axon A.T., et al. Management of Helicobacter pylori infection – the Maastricht V/Florence Consensus Report. Gut. 2017;66(1):6-30. DOI: 10.1136/gutjnl-2016-312288
51. Wermeille J., Cunningham M., Dederding J.P., Girard L., Baumann R., Zelger G., et al. Failure of Helicobacter pylori eradication: is poor compliance the main cause? Gastroenterol Clin Biol. 2002;26(3):216-219. PMID: 11981460.
52. Sanches B., Coelho L., Moretzsohn L., Vieira G Jr. Failure of Helicobacter pylori treatment after regimes containing clarithromycin: new practical therapeutic options. Helicobacter. 2008;13(6):572-576. DOI: 10.1111/j.1523-5378.2008.00649.x
53. Gong Y., Li Y., Sun Q. Probiotics improve efficacy and tolerability of triple therapy to eradicate Helicobacter pylori: a meta-analysis of randomized controlled trials. Int J Clin Exp Med. 2015;8(4):6530-6543. PMID: 26131283.
54. Bulgakov S.A. Side effects of antihelicobacter therapy. Almanac of clinical medicine. 2006;14:20-23. Russian. (Булгаков С.А. Побочные эффекты при антихеликобактерной терапии. Альманах клинической медицины. 2006;14:20-23.)
55. Marteau P., Rambaud J.C. Potential of using lactic acid bacteria for therapy and immunomodulation in man. FEMS Microbiol Rev. 1993;12:207-220. DOI: 10.1111/j.1574-6976.1993.tb00019.x
56. Zakharenko S.M., Andreeva I.V., Stetsyuk O.U. Gastrointestinal adverse drug reactions and antibioticassociated diarrhea during antibiotic therapy in outpatient practice: prevention and treatment. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2019;21(3):196-206. Russian. (Захаренко С.М., Андреева И.В., Стецюк О.У. Нежелательные лекарственные реакции со стороны ЖКТ и антибиотикоассоциированная диарея при применении антибиотиков в амбулаторной практике: профилактика и лечение. Клиническая микробиология и антимикробная химиотерапия. 2019;21(3):196-206.) DOI: 10.36488/cmac.2019.3.196-206
57. Tong J.L., Ran Z.H., Shen J., Zhang C.X., Xiao S.D. Metaanalysis: the effect of supplementation with probiotics on eradication rates and adverse events during Helicobacter pylori eradication therapy. Aliment Pharmacol Ther. 2007; 25(2):155-168. DOI: 10.1111/j.1365-2036.2006.03179.x
58. Zou J., Dong J., Yu X. Meta-analysis: Lactobacillus containing quadruple therapy versus standard triple first-line therapy for Helicobacter pylori eradication. Helicobacter. 2009; 14(5):97-107. DOI: 10.1111/j.1523-5378.2009.00716.x
59. Wang Z.H., Gao Q.Y., Fang J.Y. Meta-analysis of the efficacy and safety of Lactobacillus-containing and Bifidobacterium-containing probiotic compound preparation in Helicobacter pylori eradication therapy. J Clin Gastroenterol. 2013;47(1):25-32. DOI: 10.1097/MCG.0b013e318266f6cf
60. Zheng X., Lyu L., Mei Z. Lactobacillus-containing probiotic supplementation increases Helicobacter pylori eradication rate: evidence from a meta-analysis. Rev Esp Enferm Dig. 2013;105(8):445-453. DOI: 10.4321/s113001082013000800002
61. Li S., Huang X.L., Sui J.Z., Chen S.Y., Xie Y.T., Deng Y., et al. Meta-analysis of randomized controlled trials on the efficacy of probiotics in Helicobacter pylori eradication therapy in children. Eur J Pediatr. 2014;173(2):153-161. DOI: 10.1007/s00431-013-2220-3
62. Lv Z., Wang B., Zhou X., Wang F., Xie Y., Zheng H., et al. Efficacy and safety of probiotics as adjuvant agents for Helicobacter pylori infection: a meta-analysis. Exp Ther Med. 2015;9(3):707-716. DOI: 10.3892/etm.2015.2174
63. Zhang M.M., Qian W., Qin Y.Y., He J., Zhou Y.H. Probiotics in Helicobacter pylori eradication therapy: a systematic review and meta-analysis. World J Gastroenterol. 2015; 21(14):4345-4357. DOI: 10.3748/wjg.v21.i14.4345
64. Lü M., Yu S., Deng J., Efficacy of probiotic supplementation therapy for Helicobacter pylori eradication: a metaanalysis of randomized controlled trials. PLoS One. 2016;11(10):e0163743. DOI: 10.1371/journal.pone.0163743
65. Si X.B., Lan Y., Qiao L. A meta-analysis of randomized controlled trials of bismuth-containing quadruple therapy combined with probiotic supplement for eradication of Helicobacter pylori. Zhonghua Nei Ke Za Zhi. 2017;56(10):752-759. DOI: 10.3760/cma.j.issn.0578-1426.2017.10.009
66. Fang H. R., Zhang G.Q., Cheng J.Y., Li Z.Y. Efficacy of Lactobacillus-supplemented triple therapy for Helicobacter pylori infection in children: a meta-analysis of randomized controlled trials. Eur J Pediatr. 2019;178(1):7-16. DOI: 10.1007/s00431-018-3282-z
67. Shi X., Zhang J., Mo L., Shi J., Qin M., Huang X. Efficacy and safety of probiotics in eradicating Helicobacter pylori: a network meta-analysis. Medicine (Baltimore). 2019;98(15):e15180. DOI: 10.1097/MD.0000000000015180
68. Malfertheiner P., Megraud F., O’Morain C.A., Atherton J., Axon A.T., Bazzoli F., et al.; European Helicobacter Study Group Management of Helicobacter pylori infection – the Maastricht IV. Florence Consensus Report. Gut. 2012;61(5):646-664. DOI: 10.1136/gutjnl-2012-302084
69. WHO global strategy for containment of antimicrobial resistance. World Health Organization. Geneva: World Health Organization; 2001 (WHO/CDS/CSR/DRS/2001.2). Available at: https://apps.who.int/iris/handle/10665/66860.
70. Ouwehand A.C., Forssten S., Hibberd A.A., Lyra A., Stahl B. Probiotic approach to prevent antibiotic resistance. Ann Med. 2016;48(4):246-255. DOI: 10.3109/07853890.2016.1161232
71. Szajewska H., Guarino A., Hojsak I., Indrio F., Kolacek S., Shamir R., et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition. Use of probiotics for management of acute gastroenteritis: a position paper by the ESPGHAN Working Group for Probiotics and Prebiotics. J Pediatr Gastroenterol Nutr. 2014;58(4):531539. DOI: 10.1097/MPG.0000000000000320
72. Shim Y.H., Lee S.J., Lee J.W. Antimicrobial activity of lactobacillus strains against uropathogens. Pediatr Int. 2016;58(10):1009-1013. DOI: 10.1111/ped.12949
73. Allen-McFarlane R.S. Lactobacillus parafarraginis KU495926 inhibits multi-drug resistant and extended spectrum beta-lactamase producing gram-negative bacteria. Proceedings of ASM Microbe; June 1-5, 2017; New Orleans.
74. Romário Silva D., de Cássia Orlandi Sardi J., de Souza Pitangui N., Magri Roque S., Cristina Barbosa da Silva A., Luiz Rosalen P. Probiotics as an alternative antimicrobial therapy: current reality and future directions. J Functional Foods. 2020;73:104080. DOI: 10.1016/j.jff.2020.104080
75. Zimmermann P., Curtis N. The effect of antibiotics on the composition of the intestinal microbiota – a systematic review. J Infect. 2019;79(6):471-489. DOI: 10.1016/j.jinf.2019.10.008
76. Jernberg C., Löfmark S., Edlund C., Jansson J.K. Longterm ecological impacts of antibiotic administration on the human intestinal microbiota. ISME J. 2007;1(1):56-66. DOI: 10.1038/ismej.2007.3
77. Sjölund M., Tano E., Blaser M.J., Andersson D.I., Engstrand L. Persistence of resistant Staphylococcus epidermidis after single course of clarithromycin. Emerg Infect Dis. 2005;11:1389-1393. DOI: 10.3201/eid1109.050124
78. Jakobsson H., Wreiber K., Fall K., Fjelstad B., Nyrén O., Engstrand L. Macrolide resistance in the normal microbiota after Helicobacter pylori treatment. Scand J Infect Dis. 2007;39(9):757-763. DOI: 10.1080/00365540701299608
79. Löfmark S., Jernberg C., Jansson J.K., Edlund C. Clindamycin-induced enrichment and long-term persistence of resistant Bacteroides spp. and resistance genes. J Antimicrob Chemother. 2006;58(6):1160-1167. DOI: 10.1093/jac/dkl420
80. Dethlefsen L., Huse S., Sogin M.L., Relman D.A. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 2008;6(11):e280. DOI: 10.1371/journal.pbio.0060280
81. Zaura E., Brandt B.W., Teixeira de Mattos M.J., Buijs M.J., Caspers M.P., Rashid M.U., et al. Same exposure but two radically different responses to antibiotics: resilience of the salivary microbiome versus long-term microbial shifts in feces. MBio. 2015;6(6):e01693-15. DOI: 10.1128/mBio.01693-15
82. Palleja A., Mikkelsen K.H., Forslund S.K., Kashani A., Allin K.H., Nielsen T., et al. Recovery of gut microbiota of healthy adults following antibiotic exposure. Nat Microbiol. 2018;3(11):1255-1265. DOI: 10.1038/s41564-0180257-9
83. Elvers K.T., Wilson V.J., Hammond A., Duncan L., Huntley A.L., Hay A.D., et al. Antibiotic-induced changes in the human gut microbiota for the most commonly prescribed antibiotics in primary care in the UK: a systematic review. BMJ Open. 2020;10(9):e035677. DOI: 10.1136/bmjopen-2019-035677
84. Nel Van Zyl K., Matukane S.R., Hamman B.L., Whitelaw A.C., Newton-Foot M. Effect of antibiotics on the human microbiome: a systematic review. Int J Antimicrob Agents. 2022;59(2):106502. DOI: 10.1016/j.ijantimicag.2021.106502
85. Farnworth E.R. The evidence to support health claims for probiotics. J Nutr. 2008;138(6):1250S-1254S. DOI: 10.1093/jn/138.6.1250S
86. Sniffen J.C., McFarland L.V., Evans C.T., Goldstein E.J.C. Choosing an appropriate probiotic product for your patient: an evidence-based practical guide. PLoS One. 2018;13(12):e0209205. DOI: 10.1371/journal.pone.0209205
87. Ouwehand A.C. A review of dose-responses of probiotics in human studies. Benef Microbes. 2017;8(2):143-151. DOI: 10.3920/BM2016.0140
88. Hamilton-Miller J.M.T. Probiotics – panacea or nostrum? Nutrition Bulletin. 1996;21:199-208. DOI: 10.1111/j.1467-3010.1996.tb00853.x
89. Hatakka K., Savilahti E., Pönkä A., Meurman J.H., Poussa T., Näse L., et al. Effect of long term consumption of probiotic milk on infections in children attending day care centres: double blind, randomised trial. BMJ. 2001;322(7298):1327. DOI: 10.1136/bmj.322.7298.1327
90. Näse L., Hatakka K., Savilahti E., Saxelin M., Pönkä A., Poussa T., et al. Effect of long-term consumption of a probiotic bacterium, Lactobacillus rhamnosus GG, in milk on dental caries and caries risk in children. Caries Res. 2001;35(6):412-420. DOI: 10.1159/000047484
91. Basu S., Chatterjee M., Ganguly S., Chandra P.K. Effect of Lactobacillus rhamnosus GG in persistent diarrhea in Indian children: a randomized controlled trial. J Clin Gastroenterol. 2007;41(8):756-760. DOI: 10.1097/01.mcg.0000248009.47526.ea
92. Basu S., Paul D.K., Ganguly S., Chatterjee M., Chandra P.K. Efficacy of high-dose Lactobacillus rhamnosus GG in controlling acute watery diarrhea in Indian children: a randomized controlled trial. J Clin Gastroenterol. 2009;43(3):208-213. DOI: 10.1097/MCG.0b013e31815a5780
93. Kligler B., Cohrssen A. Probiotics. Am Fam Physician. 2008;78(9):1073-1078. PMID: 19007054.
94. Stavropoulou E., Bezirtzoglou E. Probiotics in medicine: a long debate. Front Immunol. 2020;11:2192. DOI: 10.3389/fimmu.2020.02192
95. Li B.Z., Threapleton D.E., Wang J.Y., Xu J.M., Yuan J.Q., Zhang C., et al. Comparative effectiveness and tolerance of treatments for Helicobacter pylori: systematic review and network meta-analysis. BMJ. 2015;351:h4052. DOI: 10.1136/bmj.h4052
96. Zhang Y., Li L., Guo C., Mu D., Feng B., Zuo X., et al. Effects of probiotic type, dose and treatment duration on irritable bowel syndrome diagnosed by Rome III criteria: a meta-analysis. BMC Gastroenterol. 2016;16(1):62. DOI: 10.1186/s12876-016-0470-z
97. Zhao Y., Dong B.R., Hao Q. Probiotics for preventing acute upper respiratory tract infections. Cochrane Database Syst Rev. 2022;8(8):CD006895. DOI: 10.1002/14651858.CD006895.pub4
98. Jiang W., Ni B., Liu Z., Liu X., Xie W., Wu I.X.Y., et al. The role of probiotics in the prevention and treatment of atopic dermatitis in children: an updated systematic review and meta-analysis of randomized controlled trials. Paediatr Drugs. 2020;22(5):535-549. DOI: 10.1007/s40272020-00410-6
99. Dalal R., McGee R.G., Riordan S.M., Webster A.C. Probiotics for people with hepatic encephalopathy. Cochrane Database Syst Rev. 2017;2(2):CD008716. DOI: 10.1002/14651858.CD008716.pub3
100. Liu R.T., Walsh R.F.L., Sheehan A.E. Prebiotics and probiotics for depression and anxiety: a systematic review and meta-analysis of controlled clinical trials. Neurosci Biobehav Rev. 2019;102:13-23. DOI: 10.1016/j.neubiorev.2019.03.023
101. Sanchez P., Letarouilly J.G., Nguyen Y., Sigaux J., Barnetche T., Czernichow S., et al. Efficacy of probiotics in rheumatoid arthritis and spondyloarthritis: a systematic review and meta-analysis of randomized controlled trials. Nutrients. 2022;14(2):354. DOI: 10.3390/nu14020354
102. Tao Y.W., Gu Y.L., Mao X.Q., Zhang L., Pei Y.F. Effects of probiotics on type II diabetes mellitus: a meta-analysis. J Transl Med. 2020;18(1):30. DOI: 10.1186/s12967020-02213-2
103. Timmerman H.M., Koning C.J., Mulder L., Rombouts F.M., Beynen A.C. Monostrain, multistrain and multispecies probiotics – a comparison of functionality and efficacy. Int J Food Microbiol. 2004;96(3):219-233. DOI: 10.1016/j.ijfoodmicro.2004.05.012
104. Kwoji I.D., Aiyegoro O.A., Okpeku M., Adeleke M.A. Multi-strain probiotics: synergy among isolates enhances biological activities. Biology (Basel). 2021;10(4):322. DOI: 10.3390/biology10040322
105. Collado M.C., Jalonen L., Meriluoto J., Salminen S. Protection mechanism of probiotic combination against human pathogens: in vitro adhesion to human intestinal mucus. Asia Pac J Clin Nutr. 2006;15(4):570-575. PMID: 17077078.
106. Andreeva I.V., Stetsiouk O.U. Efficacy and safety of Lactobacillus acidophilus LA-5 and Bifidobacterium lactis BB-12 combination in gastroenterology, pediatrics and allergology. Kliniceskaa mikrobiologia i antimikrobnaa himioterapia. 2016;18(2):113-124. Russian. (Андреева И.В., Стецюк О.У. Эффективность и безопасность комбинации Lactobacillus acidophilus LA-5 и Bifidobacterium lactis ВB-12 в гастроэнтерологии, педиатрии и аллергологии. Клиническая микробиология и антимикробная химиотерапия. 2016;18(2):113-124.)
107. Martins F.S., Silva A.A., Vieira A.T., Barbosa F.H., Arantes R.M., Teixeira M.M., et al. Comparative study of Bifidobacterium animalis, Escherichia coli, Lactobacillus casei and Saccharomyces boulardii probiotic properties. Arch Microbiol. 2009;191(8):623-630. DOI: 10.1007/s00203-009-0491-x
108. Tabasco R., García-Cayuela T., Peláez C., Requena T. Lactobacillus acidophilus La-5 increases lactacin B production when it senses live target bacteria. Int J Food Microbiol. 2009;132(2-3):109-116. DOI: 10.1016/j.ijfoodmicro.2009.04.004
109. Kekkonen R. Immunomodulatory effects of probiotic bacteria in healthy adults. Academic Dissertation. Helsinki. 2008. 122 p.
110. Besselink M.G., van Santvoort H.C., Buskens E., Boermeester M.A., van Goor H,. Timmerman H.M., et al. Dutch Acute Pancreatitis Study Group. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet. 2008;371(9613):651-659. DOI: 10.1016/S01406736(08)60207-X
111. Boyle R.J., Robins-Browne R.M., Tang M.L. Probiotic use in clinical practice: what are the risks? Am J Clin Nutr. 2006;83(6):1256-1264; quiz 1446-7. DOI: 10.1093/ajcn/83.6.1256
112. Natural Medicines Comprehensive Database. Lactobacillus monograph. Available at: www.naturaldatabase.com. Accessed November 21, 2022.
113. Stadlbauer V. Immunosuppression and probiotics: are they effective and safe? Benef Microbes. 2015;6(6):823-828. DOI: 10.3920/BM2015.0065
114. Salminen M.K., Tynkkynen S., Rautelin H., Saxelin M., Vaara M., Ruutu P., et al. Lactobacillus bacteremia during a rapid increase in probiotic use of Lactobacillus rhamnosus GG in Finland. Clin Infect Dis. 2002;35:1155-1160. DOI: 10.1086/342912
115. Salminen M.K., Rautelin H., Tynkkynen S., Poussa T., Saxelin M., Valtonen V., et al. Lactobacillus bacteremia, clinical significance, and patient outcome, with special focus on probiotic L. rhamnosus GG. Clin Infect Dis. 2004;38:62-69. DOI: 10.1086/380455
116. Borriello S.P., Hammes W.P., Holzapfel W., Marteau P., Schrezenmeir J., Vaara M., et al. Safety of probiotics that contain lactobacilli or bifidobacteria. Clin Infect Dis. 2003;36:775-780. DOI: 10.1086/368080
117. Hempel S., Newberry S., Ruelaz A., Wang Z., Miles J.N., Suttorp M.J., et al. Safety of probiotics used to reduce risk and prevent or treat disease. Evid Rep Technol Assess (Full Rep). 2011;(200):1-645. PMID: 23126627.
118. Esaiassen E., Hjerde E., Cavanagh J.P., Simonsen G.S., Klingenberg C. Bifidobacterium bacteremia: clinical characteristics and a genomic approach to assess pathogenicity. J Clin Microbiol. 2017;55(7):2234-2248. DOI: 10.1128/JCM.00150-17
119. Weber E., Reynaud Q., Suy F., Gagneux-Brunon A., Carricajo A., Guillot A., et al. Bifidobacterium species bacteremia: risk factors in adults and infants. Clin Infect Dis. 2015;61(3):482-484. DOI: 10.1093/cid/civ347
120. Gouriet F., Million M., Henri M., Fournier P.E., Raoult D. Lactobacillus rhamnosus bacteremia: an emerging clinical entity. Eur J Clin Microbiol Infect Dis. 2012;31(9):24692480. DOI: 10.1007/s10096-012-1599-5
121. Munoz P., Bouza E., Cuenca-Estrella M., Eiros J.M., Pérez M.J., Sánchez-Somolinos M., et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis. 2005;40:1625-1634. DOI: 10.1086/429916
122. Lu D., Yan J., Liu F., Ding P., Chen B., Lu Y., et al. Probiotics in preventing and treating chemotherapy-induced diarrhea: a meta-analysis. Asia Pac J Clin Nutr. 2019;28(4):701710. DOI: 10.6133/apjcn.201912_28(4).0005
123. Hassan H., Rompola M., Glaser A.W., Kinsey S.E., Phillips R.S. Systematic review and meta-analysis investigating the efficacy and safety of probiotics in people with cancer. Support Care Cancer. 2018;26(8):2503-2509. DOI: 10.1007/s00520-018-4216-z
124. Chen C., Wen T., Zhao Q. Probiotics used for postoperative infections in patients undergoing colorectal cancer surgery. Biomed Res Int. 2020;2020:5734718. DOI: 10.1155/2020/5734718
125. Ouyang X., Li Q., Shi M., Niu D., Song W., Nian Q., et al. Probiotics for preventing postoperative infection in colorectal cancer patients: a systematic review and metaanalysis. Int J Colorectal Dis. 2019;34(3):459-469. DOI: 10.1007/s00384-018-3214-4
126. Tang G., Zhang L., Huang W., Wei Z. Probiotics or synbiotics for preventing postoperative infection in hepatopancreatobiliary cancer patients: a meta-analysis of randomized controlled trials. Nutr Cancer. 2022;74(10):3468-3478. DOI: 10.1080/01635581.2022.2089698
127. Shu Z., Li P., Yu B., Huang S., Chen Y. The effectiveness of probiotics in prevention and treatment of cancer therapy-induced oral mucositis: a systematic review and meta-analysis. Oral Oncol. 2020;102:104559. DOI: 10.1016/j.oraloncology.2019.104559
128. Qiu G., Yu Y., Wang Y., Wang X. The significance of probiotics in preventing radiotherapy-induced diarrhea in patients with cervical cancer: a systematic review and metaanalysis. Int J Surg. 2019;65:61-69. DOI: 10.1016/j.ijsu.2019.03.015
129. Wang Y.H., Yao N., Wei K.K., Jiang L, Hanif S., Wang Z.X., et al. The efficacy and safety of probiotics for prevention of chemoradiotherapy-induced diarrhea in people with abdominal and pelvic cancer: a systematic review and meta-analysis. Eur J Clin Nutr. 2016;70(11):1246-1253. DOI: 10.1038/ejcn.2016.102
130. Devaraj N.K., Suppiah S., Veettil S.K., Ching S.M., Lee K.W., Menon R.K., et al. The Effects of probiotic supplementation on the incidence of diarrhea in cancer patients receiving radiation therapy: a systematic review with meta-analysis and trial sequential analysis of randomized controlled trials. Nutrients. 2019;11(12):2886. DOI: 10.3390/nu11122886
131. Redman M.G., Ward E.J., Phillips R.S. The efficacy and safety of probiotics in people with cancer: a systematic review. Ann Oncol. 2014;25(10):1919-1929. DOI: 10.1093/annonc/mdu106
132. Van den Nieuwboer M., Brummer R.J., Guarner F., Morelli L., Cabana M., Claasen E. The administration of probiotics and synbiotics in immune compromised adults: is it safe? Benef Microbes. 2015;6(1):3-17. DOI: 10.3920/BM2014.0079
133. Ciernikova S., Kasperova B., Drgona L., Smolkova B., Stevurkova V., Mego M. Targeting the gut microbiome: an emerging trend in hematopoietic stem cell transplantation. Blood Rev. 2021;48:100790. DOI: 10.1016/j.blre.2020.100790
134. Cohen S.A., Woodfield M.C., Boyle N., Stednick Z., Boeckh M., Pergam S.A. Incidence and outcomes of bloodstream infections among hematopoietic cell transplant recipients from species commonly reported to be in over-the-counter probiotic formulations. Transpl Infect Dis. 2016;18(5):699-705. DOI: 10.1111/tid.12587
135. Ladas E.J., Bhatia M., Chen L., Sandler E., Petrovic A., Berman D.M., et al. The safety and feasibility of probiotics in children and adolescents undergoing hematopoietic cell transplantation. Bone Marrow Transplant. 2016;51(2):262266. DOI: 10.1038/bmt.2015.275
136. Sadanand A., Newland J.G., Bednarski J.J. Safety of probiotics among high-risk pediatric hematopoietic stem cell transplant recipients. Infect Dis Ther. 2019;8(2):301306. DOI: 10.1007/s40121-019-0244-3

Просмотров

0 Аннотация

0 PDF

0 Цитирования

Пробиотики: нерешенные вопросы

Аннотация

Просмотров

Поделились

Процитировали Crossref